<DOC>
	<DOCNO>NCT00323544</DOCNO>
	<brief_summary>This study investigate whether simplified regimen daily fix dose combination Truvada ( emtricitabine tenofovir disoproxil fumarate [ DF ] ) associate reduced rate adverse event , see long term use antiretrovirals , well improve adherence compare twice daily fix dose combination Combivir .</brief_summary>
	<brief_title>SWEET : Once Daily Truvada Versus Twice Daily Combivir Treatment HIV Infection</brief_title>
	<detailed_description>The success HAART largely dependant individual 's ability adhere strictly antiretroviral regimen . Regimen characteristic affect adherence include dose frequency pill burden . Several study show improved adherence lower pill burden meta-analysis virological outcome relation pill burden show significant correlation lower pill burden well virological outcome . A systematic review study across range medical specialty demonstrate daily therapy improve adherence relative frequent dose although statistical significance demonstrate relative twice daily regimens .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>1 . Patients either sex age &gt; 18 year . 2 . HIV positive . 3 . Stable antiretroviral therapy consist efavirenz ( EFV ) give CombivirÂ® zidovudine ( AZT ) + lamivudine ( 3TC ) least 6 month . 4 . Patients viral load &lt; 50 copies/ml last 2 consecutive test &lt; 400 copies/ml &gt; 3 month . 5 . Patients require lipid lower agent must establish stable dose/frequency least 12 week prior Baseline expect continue stable dose/frequency duration study . 6 . Negative serum pregnancy test ( female childbearing potential ) . 7 . Willingness use effective contraception ( barrier coil method ) male female study treatment 30 day follow study drug completion . 8 . The ability understand sign write informed consent form , must obtain prior initiation study procedure . 1 . Pregnant lactate female . 2 . History AZT monotherapy . 3 . Use anabolic steroid , exception testosterone document hypogonadism , within 90 day prior Baseline visit . 4 . Documented parvovirus infection . 5 . Use erythropoietin within last six week . 6 . Patients blood transfusion last six week . 7 . Karnofsky score &lt; 50 . 8 . Prior history significant renal disease . 9 . Prior history osteopenia/osteoporosis . 10 . Creatinine clearance &lt; 60mL/min . 11 . AST/ALT &gt; 5 x upper limit normal ( ULN ) . 12 . Previous adefovir dipivoxil cidofovir therapy . 13 . Known history resistance ( include primary resistance ) study medication tenofovir disoproxil fumarate ( TDF ) , emtricitabine ( FTC ) , AZT , 3TC , EFV . 14 . Patients receive ongoing therapy follow ( administration follow medication must discontinue least 30 day prior Baseline visit duration study period ) : Nephrotoxic agent Probenecid Systemic chemotherapeutic agent ( i.e . cancer treatment medication ) Systemic corticosteroid Interleukin 2 ( IL 2 ) Drugs interact efavirenz Dihydroergotamine Ergotamine Midazolam Triazolam Cisapride Rifampin Ergonovine Methylergonovine 15 . Patients know hypersensitivity study medication excipients . 16 . Active , serious infection ( HIV1 infection ) require parenteral antibiotic therapy within 15 day prior Screening . 17 . Patients currently take part clinical trial take part clinical trial new chemical entity within 1 month prior Screening . 18 . Any clinical condition prior therapy , opinion investigator , would make patient unsuitable study unable comply dose requirement . 19 . Patients cancer ( except basal cell carcinoma ) . 20 . Coinfection hepatitis B virus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>HIV 1</keyword>
	<keyword>HIV 1 infection</keyword>
</DOC>